logo

Wissenschaftsportal der Französischen Botschaft in Deutschland

mariane

Programm: “Rolle und Bedeutung der In-vitro-Diagnostik in zukünftigen Gesundheitssystemen” (16. Juni 2010)

International expert meeting – In-vitro diagnostics / June 16th &17th, 2010, in the French Embassy in Germany


Wednesday, June 16th, 2010


Address of Welcome

14:00 Bernard de Montferrand, French Ambassador to Germany
14:10 Rudolf Tauber, Charité University Medicine, Berlin


Session 1: IVD in the health care system of Germany, UK and France / Present Status

Chair: Rudolf Tauber, Charité University Medicine, Berlin


14:20 In Vitro-Diagnostics in the health care system of Germany
Karl Lackner, University of Mainz/German Society for Clinical Chemistry and Laboratory Medicine (DGKL), Mayence


14:45 Designing biomarkers: the challenges for the personalized medicine of the future
Christine M’Rini, Institut Mérieux, Lyon


15:10 A partnership to deliver stratified medicine in cancer in the UK
James Peach, Cancer Research UK (CRUK), London


15:35 Understanding the regulation of In Vitro-Diagnostics in Europe
Doris-Ann Williams, British In-Vitro Diagnostics Association (BIVDA), London


Session 2: Point of Care Testing (POCT)

Chair: Penny Wilson, Technology Strategy Board, Swindon


16:35 Future Directions in PoC Testing – An Industry View
Nicholas Smith, Roche Diagnostics AG, Rotkreuz


17:00 How can nano and microtechnology increase POCT development? Two examples on how silicon and single use lab on a chip can be compatible
Christine Peponnet, CEA-Leti, Grenoble


17:25 Clinically useful Point of Care Diagnostics for Infectious Agents
Penny Wilson, Technology Strategy Board, Swindon


Thursday, June 17th, 2010

Session 3: The search for new biomarkers

Chair: Jean Chabbal, CEA-Leti, Grenoble


08:35 Clinical validation strategies for new biomarkers
François Berger, Inserm, Grenoble


09:00 Metabolite profiling – a promising tool for identification and validation of novel biomarkers
Tim Bölke, metanomics health GmbH, Berlin


09:25 Screening for novel oncology biomarker panels using both DNA and protein microarrays
John Anson, Oxford Gene Technology, Oxford


Session 4: IVD and prevention

Chair: Rudolf Tauber, Charité University Medicine, Berlin


10:35 Theranostic biochips – From biosensors to personalised medicine
Till Bachmann, Division of Pathway Medicine, University of Edinburgh, Edinburgh


11:00 EuromeDiag: a new European cluster in the medical Diagnostic field
Daniel Laune, SysDiag-CNRS/BioRad, Montpellier


11:25 Prevention of cardiovascular diseases
Michael Walter, Unfallkrankenhaus Berlin, Berlin


Session 5: IVD and therapy I

Chair: Steve Little, QIAGEN, Manchester


13:35 Influence of predictive molecular pathology on therapeutic decisions in oncology and infections
Carsten Denkert, Charité University Medicine, Berlin


14:00 High throughput RNAi and theragnostic
Xavier Gidrol, CEA, Grenoble


14:25 Business Models for Personalized Healthcare
Steve Little, QIAGEN, Manchester


Session 6: IVD and therapy II

Chair: Jean Chabbal, CEA-Leti, Grenoble


15:35 Biomarkers in preclinical and clinical drug development
Ulrike Fiedler, ProQinase GmbH, Fribourg


16:00 Rare circulating cells as a non-invasive approach to the monitoring of targeted therapy in patients with cancer; potential application to prenatal diagnosis
Yvon Cayre, Hôpital René Debré, Paris


16:25 In Vitro-Diagnostics and the value proposition of stratified medicines
Eddie Blair, Integrated Medicines Ltd, Cambridge


17:00 Closing remarks & questions
Frank Bier, Fraunhofer IBMT, Berlin